AARD
Aardvark Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.74
−1.06%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.74
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.66
- EPS estimate
- -$0.87
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +5.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $6.00
- PT range
- $6.00 – $6.00
- Analysts
- 2
0 Buy2 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.87 | -$0.66 | Beat 24.52% | — |
| May 7, 2026 | -$0.87 | -$0.99 | Miss -13.79% | — |
| Mar 23, 2026 | -$0.83 | -$0.81 | Beat 2.09% | — |
| Nov 13, 2025 | -$0.82 | -$0.75 | Beat 8.54% | — |
| Aug 13, 2025 | -$0.52 | -$0.66 | Miss -26.92% | — |
| Dec 31, 2023 | — | -$0.14 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026